Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treat...

詳細記述

保存先:
書誌詳細
出版年:Oncologist
主要な著者: Merryman, Reid W., Carreau, Nicole A., Advani, Ranjana H., Spinner, Michael A., Herrera, Alex F., Chen, Robert, Tomassetti, Sarah, Ramchandren, Radhakrishnan, Hamid, Muhammad, Assouline, Sarit, Santiago, Raoul, Wagner‐Johnston, Nina, Paul, Suman, Svoboda, Jakub, Bair, Steven M., Barta, Stefan K., Liu, Yang, Nathan, Sunita, Karmali, Reem, Burkart, Madelyn, Torka, Pallawi, David, Kevin A., Wei, Catherine, Lansigan, Frederick, Emery, Lukas, Persky, Daniel, Smith, Sonali M., Godfrey, James, Chavez, Julio, Cohen, Jonathan B., Troxel, Andrea B., Diefenbach, Catherine, Armand, Philippe
フォーマット: Artigo
言語:Inglês
出版事項: John Wiley & Sons, Inc. 2020
主題:
Brief Communications
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288660/
https://ncbi.nlm.nih.gov/pubmed/32275786
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0040
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料